Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis

References

• 1. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 14(10), 573–584 (2017).
  MedlineGoogle Scholar
• 2. Ananthakrishnan AN, Bernstein CN, Iliopoulos D et al. Environmental triggers in IBD: a review of progress and evidence. Nat. Rev. Gastroenterol. Hepatol. 15(1), 39–49 (2018).
  MedlineGoogle Scholar
• 3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 474(7351), 307–317 (2011).
  Medline CASGoogle Scholar
• 4. Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in india: the great shift East. Inflamm. Intest. Dis. 2(2), 102–115 (2017).
  MedlineGoogle Scholar
• 5. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114), 2769–2778 (2018).
  MedlineGoogle Scholar
• 6. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 380(9853), 1606–1619 (2012).
  MedlineGoogle Scholar
• 7. Harbord M, Eliakim R, Bettenworth D et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J. Crohns. Colitis. 11(7), 769–784 (2017).
  MedlineGoogle Scholar
• 8. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 19(1), 55–71 (2021).
  Medline CASGoogle Scholar
• 9. Halfvarson J, Brislawn CJ, Lamendella R et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol. 2, 17004 (2017).
  Medline CASGoogle Scholar
• 10. Rossen NG, Fuentes S, van der Spek MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149(1), 110–118.e4 (2015).
  MedlineGoogle Scholar
• 11. Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075), 1218–1228 (2017).
  MedlineGoogle Scholar
• 12. Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(1), 102–109.e6 (2015).
  MedlineGoogle Scholar
• 13. Costello SP, Hughes PA, Waters O et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321(2), 156–164 (2019).
  MedlineGoogle Scholar
• 14. Sands BE, Peyrin-Biroulet L, Loftus EV et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 381(13), 1215–1226 (2019).
  Medline CASGoogle Scholar
• 15. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment. Pharmacol. Ther. 47(2), 162–175 (2018).
  Medline CASGoogle Scholar
• 16. Agarwal A, Kedia S, Jain S et al. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest. Res. 16(4), 588–598 (2018).
  MedlineGoogle Scholar
• 17. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin. Gastroenterol. Hepatol. 16(3), 343–356.e3 (2018).
  MedlineGoogle Scholar
• 18. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777–784 (2015).
  MedlineGoogle Scholar
• 19. Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417–428 (2011).
  MedlineGoogle Scholar
• 20. Puhan MA, Schünemann HJ, Murad MH et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349, g5630 (2014).
  MedlineGoogle Scholar
• 21. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res. Synth. Methods 3(2), 111–125 (2012).
  MedlineGoogle Scholar
• 22. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265.e1–3 (2012).
  Medline CASGoogle Scholar
• 23. Jiang X-L, Cui H-F, Gao J, Fan H. Low-dose infliximab for induction and maintenance treatment in chinese patients with moderate to severe active ulcerative colitis. J. Clin. Gastroenterol. 49(7), 582–588 (2015).
  Medline CASGoogle Scholar
• 24. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699–710 (2013).
  Medline CASGoogle Scholar
• 25. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
  Medline CASGoogle Scholar
• 26. Motoya S, Watanabe K, Ogata H et al. Vedolizumab in Japanese patients with ulcerative colitis: a Phase III, randomized, double-blind, placebo-controlled study. PLoS ONE 14(2), e0212989 (2019).
  Medline CASGoogle Scholar
• 27. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376(18), 1723–1736 (2017).
  Medline CASGoogle Scholar
• 28. Suzuki Y, Motoya S, Hanai H et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J. Gastroenterol. 49(2), 283–294 (2014).
  Medline CASGoogle Scholar
• 29. Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381(13), 1201–1214 (2019).
  Medline CASGoogle Scholar
• 30. Kobayashi T, Suzuki Y, Motoya S et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J. Gastroenterol. 51(3), 241–251 (2016).
  Medline CASGoogle Scholar
• 31. Stidham RW, Lee TCH, Higgins PDR et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 39(7), 660–671 (2014).
  Medline CASGoogle Scholar
• 32. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment. Pharmacol. Ther. 47(4), 454–465 (2018).
  Medline CASGoogle Scholar
• 33. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin. Gastroenterol. Hepatol. 18(10), 2179–2191.e6 (2020).
  Medline CASGoogle Scholar
• 34. Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment. Pharmacol. Ther. 46(3), 213–224 (2017).
  Medline CASGoogle Scholar
• 35. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 53(1), 1–4 (2004).
  Medline CASGoogle Scholar
• 36. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368(5), 407–415 (2013).
  Medline CASGoogle Scholar
• 37. Juul FE, Garborg K, Bretthauer M et al. Fecal microbiota transplantation for primary Clostridium difficile infection. N. Engl. J. Med. 378(26), 2535–2536 (2018).
  MedlineGoogle Scholar
• 38. DeFilipp Z, Bloom PP, Soto MT et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381(21), 2043–2050 (2019).
  MedlineGoogle Scholar
• 39. Baunwall SMD, Lee MM, Eriksen MK et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 29, 100642 (2020).
  MedlineGoogle Scholar
• 40. Kump P, Wurm P, Gröchenig HP et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment. Pharmacol. Ther. 47(1), 67–77 (2018).
  Medline CASGoogle Scholar